Lyell Immunopharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LYEL | ALLO | 2126.HK | 2171.HK | LEGN | CABA | |
|---|---|---|---|---|---|---|
| Market cap | 378.11M | 411.13M | 1.11B | 6.48B | 4.43B | 240.75M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.4 | -1.9 | -3.0 | 96.2 | 21.7 | -1.2 |
| Price/book | 1.3 | 0.9 | 2.0 | 5.0 | 3.6 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −13.70% | +13.33% | −31.72% | −29.85% | −29.66% | −42.74% |
| Today | +43.27% | +6.25% | +7.91% | +3.36% | +6.01% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LYEL news ›Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with…
Lyell Immunopharma reports Q3 results
Lyell Immunopharma press release (LYEL): Lyell reported a net loss of $45.5 million for the third quarter ended September 30, 2026, compared to a net loss of $3 - Lyell Immunopharma press release (LYEL): Lyell reported a net loss of $45.5…
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
November 04, 2026 09:02 ET | Source: Lyell Immunopharma, Inc Lyell Immunopharma, Inc Lyell is also advancing LYL273, its GCC-targeted CAR T-cell product candidate for patients with metastatic colorectal cancer (mCRC). The program is…
Lyell Immunopharma’s (LYEL) “Buy” Rating Reaffirmed at Needham & Company LLC
Posted by Mitch Edgeman on Nov 3rd, 2026 Lyell Immunopharma (NASDAQ:LYEL – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research report issued to clients and investors on Tuesday,…
Reviewing Crescent Biopharma (NASDAQ:CBIO) and Lyell Immunopharma (NASDAQ:LYEL)
Posted by Sarita Garza on Oct 31st, 2026 Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) and Crescent Biopharma (NASDAQ:CBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
Absci (NASDAQ:ABSI) vs. Lyell Immunopharma (NASDAQ:LYEL) Critical Comparison
Posted by Danessa Lincoln on Oct 25th, 2026 Absci (NASDAQ:ABSI – Get Free Report) and Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two…
Lyell Immunopharma medical chief sells 422 shares
An automatic tax-cover sale leaves Lyell Immunopharma (LYEL) medical chief holding 19,857 shares. Stock Titan - [Form 4] Lyell Immunopharma, Inc. Insider Trading Activity Lyell Immunopharma medical chief sells 422 shares Lyell…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com3
- seekingalpha.com2
- globenewswire.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.